Natco Pharma announced its financial results for the second quarter, revealing a mixed performance with revenue growth and strategic developments.

Financial Highlights

• Consolidated revenue reached ₹1,463.00 crore.
• Net profit for the quarter stood at ₹517.90 crore on a consolidated basis.
• The Board declared a second interim dividend of ₹1.50 per equity share.

Segment Performance

The company's revenue breakdown across segments is as follows:

Key Developments

• The Board of Directors declared an interim dividend of ₹1.50 per equity share with a record date of November 20.
• Natco Pharma completed the acquisition of a 35.75% stake in Adcock Ingram Holdings Limited, South Africa, for USD 225 million through its wholly-owned subsidiary NATCO Pharma South Africa Proprietary Limited.
• The Board approved the incorporation of a wholly-owned subsidiary for demerging the Crop Health Sciences Division, aiming to enhance long-term growth and provide operational flexibility.

Strategic Initiatives

Natco Pharma continues to position itself in the pharmaceutical industry, with a focus on both domestic and international markets. The acquisition of a significant stake in Adcock Ingram Holdings and the planned demerger of the Crop Health Sciences Division demonstrate the company's commitment to strategic growth and diversification.

As Natco Pharma navigates through the global pharmaceutical landscape, the company's performance in the coming quarters may be of interest to stakeholders.

Natco Pharma , a prominent Indian pharmaceutical company, has successfully completed a significant strategic move by acquiring a 35.75% stake in Adcock Ingram Holdings Limited, a leading South African pharmaceutical firm. This acquisition, valued at approximately US$226 million (ZAR 4 billion), culminated in the delisting of Adcock Ingram from the Johannesburg Stock Exchange (JSE) on November 11, 2025.

Key Highlights of the Acquisition

Strategic Implications

The acquisition represents a significant step in Natco Pharma's global expansion strategy. By acquiring a stake in Adcock Ingram, Natco Pharma gains a strong foothold in the South African pharmaceutical market, which is crucial for its growth in the African continent.

Adcock Ingram, established in 1891, is one of South Africa's oldest pharmaceutical companies and ranks second in both the private and public pharmaceutical markets in the country. The company is renowned for its trusted medication brands, including Panado, Myprodol, Epi-Max, Citro-soda, and Allergex.

Management's Perspective

Rajeev Nannapaneni, CEO of Natco Pharma, commented on the acquisition: "This acquisition represents a significant step in our strategic growth plan across the globe. We are committed to preserving the rich legacy of Adcock Ingram while enhancing its capabilities to better serve the healthcare needs of communities across Africa and beyond."

Future Outlook

The acquisition is expected to create new opportunities for growth and innovation within the region. Natco Pharma aims to:

1. Leverage Adcock Ingram's established market position and consumer trust
2. Expand its product offerings further in South Africa and beyond
3. Enhance capabilities to serve healthcare needs across Africa

About Natco Pharma

Natco Pharma Limited is a public limited company listed on the Bombay Stock Exchange and the National Stock Exchange of India, with a market capitalization of approximately US$2 billion. Established in 1981, Natco Pharma has evolved into a diversified pharmaceutical manufacturer, focusing on research and development, manufacturing, and global marketing of both finished dosage formulations and active pharmaceutical ingredients.

The company operates in over 50 countries, with a particular focus on delivering quality medicines in oncology, cardiology, neurology, and other high-value therapeutic categories. Natco Pharma employs around 5,000 people, including over 520 scientists and researchers across its seven manufacturing and two crop health sciences facilities in India.

This strategic acquisition marks a significant milestone in Natco Pharma's global expansion efforts, potentially reshaping the pharmaceutical landscape in South Africa and beyond.